Third Point LLC Reduces Position in Danaher Co. (NYSE:DHR)

Third Point LLC trimmed its holdings in Danaher Co. (NYSE:DHRFree Report) by 5.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,450,000 shares of the conglomerate’s stock after selling 150,000 shares during the quarter. Danaher comprises 9.3% of Third Point LLC’s portfolio, making the stock its 3rd biggest holding. Third Point LLC owned about 0.33% of Danaher worth $607,845,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. AXS Investments LLC raised its holdings in Danaher by 1.4% during the 2nd quarter. AXS Investments LLC now owns 2,780 shares of the conglomerate’s stock worth $667,000 after purchasing an additional 39 shares during the last quarter. Bank of Hawaii raised its holdings in Danaher by 0.3% during the 2nd quarter. Bank of Hawaii now owns 12,578 shares of the conglomerate’s stock worth $3,019,000 after purchasing an additional 42 shares during the last quarter. Personal CFO Solutions LLC raised its holdings in Danaher by 1.6% during the 2nd quarter. Personal CFO Solutions LLC now owns 2,729 shares of the conglomerate’s stock worth $655,000 after purchasing an additional 43 shares during the last quarter. Mirova raised its holdings in Danaher by 1.1% during the 2nd quarter. Mirova now owns 4,159 shares of the conglomerate’s stock worth $998,000 after purchasing an additional 46 shares during the last quarter. Finally, Apella Capital LLC raised its holdings in Danaher by 2.0% during the 3rd quarter. Apella Capital LLC now owns 2,332 shares of the conglomerate’s stock worth $579,000 after purchasing an additional 46 shares during the last quarter. 76.71% of the stock is owned by institutional investors.

Danaher Stock Down 0.5 %

Shares of Danaher stock traded down $1.27 on Thursday, reaching $254.44. 782,892 shares of the company were exchanged, compared to its average volume of 2,741,112. Danaher Co. has a one year low of $182.09 and a one year high of $257.09. The company has a market capitalization of $188.21 billion, a price-to-earnings ratio of 40.02, a PEG ratio of 3.87 and a beta of 0.85. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average of $238.16 and a 200 day moving average of $231.13.

Danaher (NYSE:DHRGet Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The company had revenue of $6.41 billion for the quarter, compared to analysts’ expectations of $6.10 billion. During the same quarter in the prior year, the business posted $2.87 EPS. The business’s revenue was down 10.2% compared to the same quarter last year. On average, equities research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date of this dividend is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is 15.02%.

Wall Street Analyst Weigh In

DHR has been the subject of several recent research reports. Royal Bank of Canada boosted their price objective on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. TheStreet upgraded Danaher from a “c+” rating to a “b-” rating in a research report on Friday, December 8th. KeyCorp boosted their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, Citigroup boosted their price objective on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Seven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $266.00.

View Our Latest Report on DHR

Insider Activity at Danaher

In related news, Director Walter G. Lohr sold 3,289 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $251.15, for a total value of $826,032.35. Following the sale, the director now owns 14,129 shares in the company, valued at approximately $3,548,498.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Walter G. Lohr sold 3,289 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $251.15, for a total value of $826,032.35. Following the transaction, the director now owns 14,129 shares in the company, valued at approximately $3,548,498.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,957 shares of company stock worth $8,265,802. Company insiders own 11.10% of the company’s stock.

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.